Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

MCET RSS Feed
Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MyDogBuster, Dip66, locksflooring, roberteliates, HorseShoe Man
Search This Board:
Last Post: 7/24/2014 9:58:28 AM - Followers: 574 - Board type: Free - Posts Today: 3

 

ThinkingAlpha.com 
#1 Network for Active Traders






MultiCell Technologies (MCET) 

 

 
Ticker - MCET (U.S. Reporting: SEC Filer) 

Number of shares outstanding: 3.73 Billion

Market Value: $6,304,720 a/o May 13, 2014

Estimated Float: 3.38 Billion a/o May 13, 2004
 

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)
 


Partners

AmarinCorningPhizer



Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development

 MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.

                                       MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.

 MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.

 MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

Therapeutic Candidate

Indication

Discovery Optimization

Preclinical Development

Phase 1

Phase 2

Phase 3

MCT-125

PMSF

         

MCT-465

Cancer

         

MCT-475

Cancer

         

MCT-485

Cancer

         
 

From Press Release: If MCT-125 is approved for the treatment of fatigue in MS patients by the FDA and other such regulatory agencies, and is successfully commercialized, Multicell estimates MCT-125 could generate up to $3 billion in cumulative worldwide sales during the time MCT-125 is under patent protection. If such revenue forecasts are realized by MCT-125, under the terms of the agreement, Amarin could receive up to $275 million in milestone payments and cumulative royalty payments during the same period. Continue >>

 

CDSS Retained by Multicell Technologies to manage MCT-125 Phase IIb Clinical Trial

illingworth Research MCT-125

http://illingworthresearch.com/2011/03/22/cdss-retained-by-multicell-technologies-to-manage-mct-125-phase-iib-clinical-trial/


Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.


MultiCell Technologies, Inc. Corporate Headquarters

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

MultiCell Technologies Inc. Headquarters

68 Cumberland Street, Suite 301
Woonsocket, RI 02895
Office: (401) 762-0045
Email: info@multicelltech.com
Web: www.multicelltech.com

Find us on Google Maps  
    http://www.facebook.com/MCET.OB  
 


 Management and Board of Directors


W. Gerald Newmin, Chairman and Chief Executive Officer
Mr. W. Gerald Newmin joined the Company in June 1995.  Mr. Newmin currently serves as Chairman of the Board of Directors and Acting Chief Executive Officer of the Company.  Mr. Newmin is also Chairman and CEO, and a director of Xenogenics Corporation, a majority-owned subsidiary of the Company; Chairman and CEO, and a director of MCT Rhode Island Corp., a wholly-owned subsidiary of the Company; and, CEO and a director of MultiCell Immunotherapeutics, Inc., a majority-owned subsidiary of the Company.  Mr. Newmin has managed NYSE and American Stock Exchange Fortune 500 companies.  Mr. Newmin has been President of Health America Corporation, then the nation’s largest publicly held HMO management company.  Mr. Newmin was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured.  Mr. Newmin was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive.  Mr. Newmin was instrumental in Whittaker’s entry into the US and international health care markets.  Mr. Newmin was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States.  Mr. Newmin retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003.  Mr. Newmin has a Bachelors degree in Accounting from Michigan State University.

Stephen Chang, PhD (Vice President, Research and Development)
Stephen M. Chang, Ph.D., Director
Dr. Stephen Chang has served as a director of the Company since June 2004.  Dr. Chang has been Chief Scientific Officer (CSO) of Stemgent, Inc. since January 2008.  Prior to joining Stemgent, Dr. Chang served as President and CEO of MultiCell from July 2006 until December 2007, and as President of MultiCell from September 2005 to June 2006.  Prior to joining Multicell, Dr. Chang was the CEO of Astral Immunotherapy which was acquired by Multicell Technologies in September 2005.  Prior to joining Astral, Dr. Chang was CSO and vice president of Canji Inc. / Schering Plough Research Institute in San Diego from 1998 to 2004.  Dr. Chang has also held senior management positions at Chiron and Viagene.  Dr. Chang is currently president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative life saving medications.  Dr. Chang is also a board member of Histogen a privately held company in regenerative medicine.  Dr. Chang earned his doctoral degree in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine.

Grant Miller,  MBA/CFO
Grant Miller, Director
Mr. Miller, appointed to the Board in 2012, received his B.A. from Loma Linda University in Riverside, CA and an MBA in Finance from the University of San Diego, in San Diego, CA. Mr. Miller is Chief Financial & Operating Officer of Sandel Avionics and has served as Chief Financial Officer of Rapid Bridge, LLC, General Manager & Division Controller of Scubapro, Chief Financial Officer of USA Broadband, Inc., Chief Financial Officer & Senior VP Operations of Alitum, and held several positions with WorldXchange and Time Warner Cable, including International Director of Development in Spain and Portugal, Regional Vice President Finance, Corporate Mergers & Acquisitions Analyst, Manager, Finance and Information Systems and Financial Analysis.

Edward Sigmond
Edward Sigmond, Director
Mr. Edward Sigmond has served as a director of the Company since May 2000.  Mr. Sigmond has been in sales, marketing and operations management for the past 20 years.  Mr. Sigmond has served as president of Kestrel Holdings, Inc., a holding company, since its inception in 1997.  Mr. Sigmond served as president of Kestrel Development, a Texas based real estate development company, from 1993 to 1998 when it was dissolved.  Mr. Sigmond studied Marketing and Chemistry at Duquesne University.

Thomas A. Page, Director
Mr. Thomas Page has served as a director of the Company since September 2003.  Mr. Page is Director Emeritus and former Chairman of the Board and CEO of Enova Corporation and San Diego Gas and Electric Company (now part of Sempra Energy).  Prior to the formation of Sempra Energy Corporation as a holding company in 1996, at various times Mr. Page was SDG&E’s chairman, president and CEO and  held one or more of these positions until his retirement in 1998.  Mr. Page joined SDG&E in 1978 as executive vice president and COO.  In 1981, he was elected president and CEO and added the chairmanship in 1983.  Mr. Page has been active in numerous industrial, community and governmental associations and has funded medical research.  He is a director of the San Diego Regional Economic Development Corporation, Community National Bank, Sys Technologies and is an advisory director of Sorrento Ventures.  Mr. Page earned a Bachelor of Science degree in civil engineering, a masters degree in industrial administration and was awarded a doctorate in management, all from Purdue University.  Mr. Page has been licensed as an engineer and as a certified public accountant (CPA).  Mr. Page also serves on the University of California Presidents Council on the National Laboratories.


Scientific Advisors

Alan Tuchman, M.D.
Dr. Tuchman is concurrently in private practice and is Clinical Professor of Neurology at New York Medical College.  He is also the Principal of a healthcare and neuroscience consulting firm.  From 1997 to 2001, Dr. Tuchman was Senior Vice President of Equity Research for Oscar Gruss & Son (Member of the New York Stock Exchange), New York, New York, where he conducted investment research in medical and biotechnology and helped develop marketing strategies for healthcare companies.  Prior to this, he was Vice Dean of Clinical Affairs for New York Medical College where he developed and directed clinical care and medical education policy for 29 affiliated hospitals and served as Professor and Vice Chairman and Program Director for Neurology Residency in the Department of Neurology at the same institution.  At the Lincoln Medical and Mental Health Center, Dr. Tuchman held the positions of Medical Director for the 560-bed hospital from 1990 to 1991 and Director of the Department of Neurology from 1979 to 1994.  Serving in the United States Air Force as Major, he was Chief of Neurology Service for a 16-state region.  Dr. Tuchman earned his B.S. in Chemistry in 1968 from the City College of New York, his M.D. in 1972 from the University of Cincinnati College of Medicine, and his MBA from Columbia University in 1996. He completed his internship at New York Medical College and his residency at the Mount Sinai Hospitals Department of Neurology.  Dr. Tuchman was a clinical fellow in multiple sclerosis at the Albert Einstein College of Medicine Department of Neurology.  Dr. Tuchman is certified by the American Board of Psychiatry and Neurology and the American Society of Neurorehabilitation and is licensed in New York, New Jersey and Ohio.  Dr. Tuchman served as the President of the Epilepsy Society of Southern New York from 1987 1992.

 







ThinkingAlpha.com
#1 Network for Active Traders

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MCET
Current Price
Volume:
Bid Ask Day's Range
Wiki
MCET News: Quarterly Report (10-q) 07/15/2014 09:15:45 AM
MCET News: MultiCell Technologies Files U.S. and International Patent Applications for the Treatment of Liver Cancer 03/20/2014 08:39:00 AM
MCET News: MultiCell Technologies Files U.S. and International Patent Applications for the Treatment of Liver Cancer 03/20/2014 08:39:00 AM
PostSubject
#34376  Sticky Note MultiCell Technologies, Inc. OTCQB TraderpennyX 04/03/14 03:57:31 AM
#27347  Sticky Note PATENT INFORMATION roberteliates 03/28/13 07:50:04 AM
#37062   There are no timeline goals. simon wagstaff 07/24/14 09:58:28 AM
#37061   What do you mean vague, we can expect jeffshir 07/24/14 09:17:58 AM
#37060   Run is coming any time !! newlonginvest 07/24/14 07:58:53 AM
#37058   Another vague response on MCET's facebook...I don't think Glitch07 07/23/14 05:38:44 PM
#37057   Hey man, so sorry...I was a little tipsy Thrashing21 07/23/14 02:51:38 PM
#37056   Finally got all my 6s filled - sitting Thrashing21 07/23/14 02:49:50 PM
#37055   Adios fellas!! bluejacket6 07/23/14 12:30:09 PM
#37054   That's odd I thought there dumping shares jtrenee89 07/23/14 10:45:48 AM
#37053   Don't even worry about them. MCET rises roberteliates 07/23/14 09:40:25 AM
#37052   Getting ready to pick up from the bottom roberteliates 07/23/14 09:38:49 AM
#37051   You guy's are working hard on this one? HorseShoe Man 07/23/14 07:48:21 AM
#37050   I knew it! That's how MCET works. simon wagstaff 07/23/14 06:41:52 AM
#37049   8.75% held by insiders is incorrect. That number simon wagstaff 07/23/14 06:40:26 AM
#37048   Or they Invest in the Co & BuyBack Decarz 07/23/14 06:10:24 AM
#37047   Bluejacket 6 . . bontooth 07/23/14 03:21:57 AM
#37046   i'm new here, what's the story on this snakecorleone 07/22/14 09:48:16 PM
#37045   THERE IS NOW 3.9 BILLION SHARES OUTSTANDING. UNLESS Dip66 07/22/14 09:29:45 PM
#37044   Where ya got the promoted information from? sup105 07/22/14 08:23:28 PM
#37043   I'm all in just as you but let's sicmoney 07/22/14 08:20:55 PM
#37042   Being promoted - I'm buying in tomorrow for Thrashing21 07/22/14 06:17:56 PM
#37041   Yea sup105 07/22/14 05:24:46 PM
#37039   Absolutely Bluejacket. . BUY! BUY! BUY! & HOLD I"ll accept Decarz 07/22/14 04:25:03 PM
#37038   http://www.hotstocked.com/article/80602/multicell-technologies-inc-otcmkts-mcet- Decarz 07/22/14 04:18:15 PM
#37037   I have my sell order set at $10. bluejacket6 07/22/14 04:12:13 PM
#37036   Will go up 3x time shortly newlonginvest 07/22/14 04:05:47 PM
#37035   Decarz, better check you BB history cause your ctvette2003 07/22/14 04:03:56 PM
#37034   How is this potentially possibly real? What will simon wagstaff 07/22/14 03:55:20 PM
#37033   I think Potentially MCET has an Opportunity to Decarz 07/22/14 03:39:53 PM
#37032   People are just down on paper. ..if you Decarz 07/22/14 03:22:23 PM
#37031   That 82 million will be gone in minutes HorseShoe Man 07/22/14 02:41:21 PM
#37030   once de 6'ss are gone , time to dirkie 07/22/14 02:37:13 PM
#37029   Thanks LOL too late for that though. Half bluejacket6 07/22/14 02:34:10 PM
#37028   Someone's doings some covering HorseShoe Man 07/22/14 02:33:02 PM
#37027   Maybe MCET puts out a PR or updates Jeppy D 07/22/14 02:31:23 PM
#37026   All this bitching has landed us #4 on bluejacket6 07/22/14 02:29:07 PM
#37025   I'll remind you, never follow the idiot analyst Jeppy D 07/22/14 02:27:28 PM
#37024   You seriously think this is going to .0018. bluejacket6 07/22/14 02:10:34 PM
#37023   Or... you will potentially have lost 50% if Jeppy D 07/22/14 02:08:47 PM
#37022   Remind me never to follow the idiot analyst bluejacket6 07/22/14 02:06:56 PM
#37021   But You Will Potentially Make 3x's as much Decarz 07/22/14 12:11:08 PM
#37020   he have shorted the stock and try to gggamm338 07/22/14 11:58:26 AM
#37019   Im still standing by this post Decarz 07/22/14 11:53:31 AM
#37018   "So, with my modest starter at 24, what simon wagstaff 07/22/14 11:51:42 AM
#37017   Yes, think of me surrounded by all those simon wagstaff 07/22/14 11:42:33 AM
#37016   Thanks Simon. Every time I see that mrroundtree 07/22/14 11:36:33 AM
#37015   "New staffers" from Facebook? simon wagstaff 07/22/14 11:33:22 AM
#37014   So, with my modest starter at 24, what Highlandmike 07/22/14 11:27:22 AM
#37013   yes, I got banned from their face book simon wagstaff 07/22/14 11:25:20 AM
#37012   When is this scum company going to churn Dip66 07/22/14 11:15:37 AM
#37011   Watch it! Volume is way up? 100 million today? HorseShoe Man 07/22/14 11:00:56 AM
PostSubject